Cargando…

Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018

Tuberculosis patients “resistant to isoniazid and susceptible to rifampicin (Hr-TB)” remain neglected, despite a high burden and poor outcomes. The World Health Organization (WHO) recommends a 6 month regimen consisting of levofloxacin, rifampicin, ethambutol, and pyrazinamide (LRZE) to treat Hr-TB....

Descripción completa

Detalles Bibliográficos
Autores principales:	Sayfutdinov, Zayniddin, Kumar, Ajay, Nabirova, Dilyara, Gadoev, Jamshid, Turaev, Laziz, Sultanov, Sanjar, Alaverdyan, Sevak, Parpieva, Nargiza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001662/ https://www.ncbi.nlm.nih.gov/pubmed/33799350 http://dx.doi.org/10.3390/ijerph18062965

Ejemplares similares

Universal Access to Xpert MTB/RIF Testing for Diagnosis of Tuberculosis in Uzbekistan: How Well Are We Doing?
por: Turaev, Laziz, et al.
Publicado: (2021)

Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
por: Usmanova, Ruzilya, et al.
Publicado: (2021)

Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018
por: Ismatov, Bakhtiyor, et al.
Publicado: (2021)

Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012–2019: Are We on the Right Track?
por: Yuldashev, Sharofiddin, et al.
Publicado: (2021)

Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018
por: Safaev, Khasan, et al.
Publicado: (2021)

Characteristics and Treatment Outcomes of Patients with Tuberculosis Receiving Adjunctive Surgery in Uzbekistan
por: Riskiyev, Anvar, et al.
Publicado: (2021)

Adverse Drug Reactions among Children with Tuberculosis in Tashkent, Uzbekistan, 2019
por: Abdusalomova, Makhliyo, et al.
Publicado: (2021)

Risk Factors for Unfavorable Treatment Outcomes among the Human Immunodeficiency Virus-Associated Tuberculosis Population in Tashkent City, Uzbekistan: 2013–2017
por: Massavirov, Sherali, et al.
Publicado: (2021)

Operational Research to Inform Programmatic Approaches to the Management of Tuberculosis in Uzbekistan
por: Gadoev, Jamshid, et al.
Publicado: (2021)

Incidence Rate and Risk Factors for Tuberculosis among People Living with HIV: A 2015–2017 Cohort from Tashkent, Uzbekistan
por: Sadirova, Dilbar, et al.
Publicado: (2021)

Diagnostic Procedures, Diagnoses, and Treatment Outcomes of Patients with Presumptive Tuberculosis Pleural Effusion in Uzbekistan
por: Abdugapparov, Fazlkhan, et al.
Publicado: (2021)

1433. Factors Associated with Unsuccessful Treatment Outcomes among Patients with Rifampicin Resistant Tuberculosis - Tajikistan, 2015-2020
por: Tilloeva, Zulfiya Haybullo, et al.
Publicado: (2022)

Recurrent tuberculosis and associated factors: A five - year countrywide study in Uzbekistan
por: Gadoev, Jamshid, et al.
Publicado: (2017)

445. High HCV Treatment Success among People Living with HIV - Kyrgyzstan, 2018-2021
por: Kyzy, Nasyat Kemelbek, et al.
Publicado: (2022)

2389. Surveillance evaluation of COVID-19 pharmacovigilance—Karakalpakstan, Uzbekistan, 2022
por: Tursinov, Yunis, et al.
Publicado: (2023)

Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study
por: Gadoev, Jamshid, et al.
Publicado: (2015)

Factors associated with COVID-19 vaccine confidence among primary care providers in Kazakhstan, March–April 2021
por: Nabirova, Dilyara, et al.
Publicado: (2023)

Corrigendum: Factors associated with COVID-19 vaccine confidence among primary care providers in Kazakhstan, March–April 2021
por: Nabirova, Dilyara, et al.
Publicado: (2023)

1528. Retrospective cohort study of factors associated with non-initiation of antiretroviral therapy among adults newly diagnosed with HIV in Andijan, Uzbekistan, 2018-2021
por: Usmanov, Shokhruh, et al.
Publicado: (2023)

Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2020)

Effectiveness and Safety of a Shorter Treatment Regimen in a Setting with a High Burden of Multidrug-Resistant Tuberculosis
por: Trubnikov, Aleksandr, et al.
Publicado: (2021)

On the implementation of the Biological Threat Reduction Program in the Republic of Uzbekistan
por: Tuychiev, Laziz, et al.
Publicado: (2013)

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
por: Trauer, James M., et al.
Publicado: (2016)

Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2020)

Fatal poisoning by isoniazid and rifampicin
por: Sridhar, A., et al.
Publicado: (2012)

Isoniazid- and rifampicin-induced thrombocytopenia
por: Yakar, Fatih, et al.
Publicado: (2013)

Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2016)

Factors Associated with an Outbreak of COVID-19 in Oilfield Workers, Kazakhstan, 2020
por: Nabirova, Dilyara, et al.
Publicado: (2022)

Clinical Features of COVID-19 in Uzbekistan
por: Kim, KyungHee, et al.
Publicado: (2020)

Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Nair, P., et al.
Publicado: (2022)

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
por: du Cros, Philipp, et al.
Publicado: (2021)

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Moe, S., et al.
Publicado: (2023)

Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in Uzbekistan
por: Wharton-Smith, Alexandra, et al.
Publicado: (2021)

Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro
por: Anderson, Ronald, et al.
Publicado: (2018)

Factors Associated with Unfavourable Treatment Outcomes in Patients with Tuberculosis: A 16-Year Cohort Study (2005–2020), Republic of Karakalpakstan, Uzbekistan
por: Gadoev, Jamshid, et al.
Publicado: (2021)

Protective Effects of Metallothionein on Isoniazid and Rifampicin-Induced Hepatotoxicity in Mice
por: Lian, Yong, et al.
Publicado: (2013)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_42fsjsmgo5g94s8bfigg0svc7g